

1/38




FIG. 2A





FIG. 2B



3/38

FIG. 3A




FIG. 3B





FIG. 3C



4/38




FIG. 4A






FIG. 4B

5/38

**FIG. 5A****FIG. 5B**




FIG. 6A




FIG. 6B




FIG. 7

7/38




FIG. 8A








FIG. 8B



8/38

**FIG. 9A****FIG. 9B**

9/38

**FIG. 10A****FIG. 10B**

10/38

**FIG. 11A****FIG. 11B**




FIG. 12A







FIG. 12B



12/38

**FIG. 13**


13/38

**FIG. 14****FIG. 15**

14/38


**FIG. 16****FIG. 17**

15/38



**FIG. 18**

16/38


PC3 (PTEN Null) Prostate

**FIG. 19**


17/38

**FIG. 20****FIG. 22**


18/38

**FIG. 21**


19/38

**FIG. 23**


20/38

**FIG. 24**


21/38

**FIG. 25**



22/38

**FIG. 26**

23/38


Trastuzumab + GDC-0032 Combinations in BT474 (Breast)**Dose Groups****FIG. 27**

24/38



**FIG. 28****FIG. 30**

25/38


**Trastuzumab (Herceptin®), Docetaxel, GDC-0032,
and Combinations in BT474M1 (Breast)**

**FIG. 29**


26/38

**FIG. 31****FIG. 32**

27/38


**FIG. 33**

28/38

**FIG. 34**


29/38

**GDC-0032 + DTX in A549 (KRAS^{G12S}, P13K^{M772X,N996H})
NSCLC Xenograft Model (Day 21, PRC)**

**FIG. 35**

30/38

**GDC-0032 + DTX in H520 (p53^{mut}) NSCLC Xenograft Model
(Day 28, PRC)**

**FIG. 36**




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41

Combination of GDC-0032 and paclitaxel on intermittent and daily schedules in the MCF-7 Breast Cancer Xenograft Model




FIG. 42

Triple combinations of GDC-0032 with Trastuzumab and Pertuzumab in the KPL-4 Breast Cancer Xenograft Model




FIG. 43

Combination of GDC-0032 with Paclitaxel, Carboplatin, anti-VEGF (B20-4.1.1) in the H292 NSCLC Xenograft Model




FIG. 44